Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07139522

Dexamethasone Versus Magnesium Sulphate as an Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Plane Block for Postoperative Analgesia in Elective Caesarean Section Under Spinal Anesthesia

The Efficacy of Dexamethasone Versus Magnesium Sulphate as an Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Plane Block for Postoperative Analgesia in Elective Caesarean Section Under Spinal Anesthesia: A Randomized Controlled Trial.

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
150 (estimated)
Sponsor
Cairo University · Academic / Other
Sex
All
Age
18 Years – 35 Years
Healthy volunteers
Not accepted

Summary

This study aims to compare the efficacy of adding dexamethasone and magnesium sulfate as an adjuvant to bupivacaine in bilateral erector spinae block in postoperative pain control in patients undergoing caesarean section under spinal anesthesia.

Detailed description

Caesarean section (CS) is the most common abdominal surgery among women worldwide. Inadequately treated postoperative pain can contribute significantly to morbidity of surgical patients, resulting in the delay of patients' recovery and ability to return to daily functional activities, increased incidence of chronic pain, and post-traumatic stress syndrome. The ultrasound-guided erector spinae plane (ESP) block is a recently described interfascial paraspinal plane technique that was initially used by Forero et al. for providing thoracic analgesia when performed at the level of T5 transverse process. Since the pain experienced after caesarean delivery using a Pfannenstiel incision has both a somatic and visceral component. Magnesium sulfate (MgSO4) may be helpful as an analgesic adjuvant in regional anesthesia because it improves and prolongs the analgesic effect of local anesthetics. Dexamethasone is a potent glucocorticoid medication commonly used as an adjuvant to reduce postoperative pain. The mechanisms of perineurally administered dexamethasone are likely attributed to complex interactions, including direct inhibition of signal transmission in nociceptive C fibres, local vasoconstriction, and reduced local inflammation.

Conditions

Interventions

TypeNameDescription
DRUGBupivacainePatients will receive 20 ml of 0.25% isobaric bupivacaine.
DRUGDexamethasonePatients will receive 20 ml of (0.25% isobaric bupivacaine and 4mg of dexamethasone).
DRUGMagnesium sulphatePatients will receive 20 ml of (0.25% isobaric bupivacaine and 200mg of magnesium sulphate).

Timeline

Start date
2023-12-01
Primary completion
2025-12-01
Completion
2025-12-01
First posted
2025-08-24
Last updated
2025-08-24

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT07139522. Inclusion in this directory is not an endorsement.